Toro Labs Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist. One of the most researched compounds in metabolic science.
Key Details
– 30mg per vial
– Lyophilised (freeze dried) powder
– Requires reconstitution with bacteriostatic water
– Batch tested via HPLC analysis
– Toro Labs authenticated product
Research Benefits
– Dual-action receptor agonist targeting both GIP and GLP-1 receptors
– Extensively studied for superior weight reduction outcomes
– Supports improved insulin sensitivity and glycaemic control
– May reduce visceral fat more effectively than single-receptor agonists
– Sustained appetite suppression with favourable tolerability profile
Suggested Research Protocol
– Starting dose: 2.5mg per week for 4 weeks
– Titrate by 2.5mg every 4 weeks as tolerated
– Maintenance dose: 10mg to 15mg per week
– Administered via subcutaneous injection
– Store reconstituted vial refrigerated at 2 to 8C
Quality Assurance: Every vial is batch coded and lab verified. Full HPLC purity reports available on request. Manufactured under strict ISO conditions by Toro Laboratories.
Reviews
There are no reviews yet.